Galapagos receives EUR2.5 million IWT grant for IBD research

Galapagos receives EUR2.5 million IWT grant for IBD research 
MECHELEN, BELGIUM -- (Marketwire) -- 01/30/13 --  Galapagos  NV
(Euronext: GLPG) announced today  that it has been awarded a EUR2.5
million grant from the Flemish agency for Innovation  by Science and
Technology (IWT) for inflammatory bowel disease (IBD)
research  and
development.  The goal of this 2.5-year project is to identify new
therapeutic compounds for future treatment of IBD patients. 
Inflammatory  bowel disease (IBD) is a chronic, uncontrolled
inflammation of the intestinal mucosa.  Crohn's disease (CD) and
ulcerative colitis (UC) are the two main types of IBD; both diseases
have an autoimmune component.  The introduction
of  anti-TNF alpa
antibodies has  changed the treatment  of refractory patients,
but 
only one third of the patients  will achieve long-term remission.  As
such,
the medical need in this patient segment is very high. 
The  general purpose of the IWT-funded program  is to gain better
insight in the roles  of  GPR43  and  two  undisclosed  targets  in
the pathobiology of chronic
inflammatory   disorders,  in  order  to 
understand  their  therapeutic value.
 Galapagos will collaborate in
this project with Professor Dr Paul Rutgeerts and Professor  Dr
Severine Vermeire from the  Catholic University of Leuven, and the
research group of Professor Dr Martine De Vos at Ghent University. 
Galapagos  has been working in the anti-inflammatory  field for a
long time, and has  several projects with IBD as potential indication.
 The first compound that
will  be tested in IBD patients is 
GLPG0974, an inhibitor of target GPR43 (also
known  as FFA2).   This
target  is one  of the  three whose  role in IBD will be investigated
 in this  IWT-funded project.   Galapagos has  recently completed a
second  Phase I  clinical study  with GLPG0974,  and results  are
expected to be reported  later this quarter.  In April Galapagos  will
start a Proof of Concept
study with GLPG0974 in UC. 
"After  RA, IBD is the second autoimmune disease focus for Galapagos.
 With this
grant  we will  get a  better understanding  of the  cause
of IBD, and this will
contribute  to the  search for  better
medicines,"  said Piet  Wigerinck, CSO of Galapagos.   "The knowledge
that will come  from this research will provide more
insight into the
potential of our programs for use in this indication." 
About IBD 
Inflammatory  bowel diseases (IBD)  are disorders of  multi-factorial
cause that
present  as a multitude of phenotypes, clinical behaviors
and severity. Crohn's
disease  (CD) and ulcerative  colitis (UC) are 
the two main  types of IBD. The
peak  age of onset is 15 to 30 years 
old, with a second, smaller peak occurring
in  individuals aged 50 to
 70, with the prevalence  rate of IBD  reaching up to 396/100,000
persons. The  hallmark  of  IBD  is  chronic  uncontrolled
inflammation of the intestinal
mucosa,  involving a  pathological
response  in both  innate and adaptive immune
system.   The 
pathogenesis  is  an  interplay  of factors as diverse as
genetic
susceptibility,  the  external  environment,  infectious 
agents,  the commensal
enteric  microbiota,  and  (mucosal)  immune 
system  dysfunction. However, the current  understanding of the
pathogenesis  remains limited.  The characteristic
inflammatory 
response begins with infiltration  of neutrophils and
macrophages,
which   release   chemokines  and  cytokines.   These 
in  turn  exacerbate the
dysfunctional immune response and activate
cellular and humoral responses in the gut mucosa. 
About Galapagos 
Galapagos   (Euronext: GLPG;   OTC:   GLPYY)  is  a  mid-size 
clinical stage
biotechnology  company  specialized  in  the  discovery
and development of small
molecule  and antibody  therapies with  a
novel  mode-of-action.  The Company is progressing four clinical, six
pre-clinical, and 30 discovery programs in cystic
fibrosis,
inflammation, antibiotics, metabolic disease, and other
indications.
Its  lead program is GLPG0634, an orally-available,
selective inhibitor of JAK1,
for  the treatment  of rheumatoid 
arthritis and  potentially other inflammatory
diseases.   In two
four-week Phase 2 studies, GLPG0634 showed improvement in the signs 
and symptoms of rheumatoid  arthritis and a unique  safety profile.
A
6-month  Phase 2b study is expected to start Q2 2013 with topline
data expected in Q4  2014.  AbbVie  and  Galapagos  signed  a
worldwide license agreement whereby
AbbVie  will be responsible for 
further development and commercialization after
Phase 2b.  Galapagos
is also progressing two other clinical development programs
with 
clinical readouts  expected in  2013: GLPG0187, a  novel integrin
receptor
antagonist  in  development  for  metastasis,  is  in  a
Phase 1b patient study;
GLPG0974  is the first inhibitor of GPR43, 
which is currently often referred to as  FFA2.  It will  be evaluated
for  the treatment of  IBD.  This program is in Phase 1 and a Proof
of Concept Phase 2 study will start in Q2 2013. The  Galapagos Group,
including fee-for-service  companies BioFocus, Argenta and Fidelta, 
has over 800 employees and operates facilities in five countries,
with
global headquarters in Mechelen, Belgium.  Further information
about the company
and its drug development programs can be found
online at: www.glpg.com 
Galapagos forward-looking statements 
This release may contain forward-looking statements, including,
without limitation, statements containing the words "believes,"
"anticipates," "expects," "intends," "plans," "seeks," "estimates,"
"may," "will," "could,"
"stands to," and "continues," as well as
similar expressions. Such forward-looking statements may involve
known and unknown risks, uncertainties and other factors which might
cause the actual results, financial condition, performance
or
achievements of Galapagos, or industry results, to be materially
different
from any historic or future results, financial conditions,
performance or achievements expressed or implied by such
forward-looking statements. Given these uncertainties, the reader is
advised not to place any undue reliance on
such forward-looking
statements. These forward-looking statements speak only as of the
date of publication of this document. Galapagos expressly disclaims
any
obligation to update any such forward-looking statements in this
document to
reflect any change in its expectations with regard thereto
or any change in events, conditions or circumstances on which any
such statement is based, unless
required by law or regulation. 
Galapagos receives EUR2.5 million IWT grant for IBD research:
http://hugin.info/133350/R/1673980/545024.pdf 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that: 
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Galapagos NV via Thomson Reuters ONE 
[HUG#1673980] 
Contact 
Galapagos NV
Dr Piet Wigerinck
Chief Scientific Officer
Tel. +32 477 627103 
Elizabeth Goodwin
Director Investor Relations
Tel: +31 6 2291 6240
ir@glpg.com
 
 
Press spacebar to pause and continue. Press esc to stop.